Clinical Trial Update: Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating Maridebart Cafraglutide for heart failure with preserved or mildly reduced ejection fraction in people with obesity is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Mildly Reduced Ejection Fraction
• Heart Failure with Preserved Ejection Fraction
• Obesity

Drugs mentioned

• Maridebart Cafraglutide

Snippet

Sponsor: Amgen | Conditions: Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction | Phase 3 | Status: RECRUITING